Online Only Articles

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Hematology, University Medical Center Groningen, the Netherlands
Department of Hematology, University Medical Center Groningen, the Netherlands
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands;Lymphoma and Myeloma Center Amsterdam (LYMMCARE), the Netherlands
Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands
Biometric Department, NKI-AVL, Amsterdam, the Netherlands
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands;Lymphoma and Myeloma Center Amsterdam (LYMMCARE), the Netherlands
Vol. 104 No. 4 (2019): April, 2019 https://doi.org/10.3324/haematol.2018.196899